Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Blood

Volumn 120, Issue 25, 2012, Pages 4945-4951

  Sekeres, Mikkael A ^a   Tiu, Ramon V ^a   Komrokji, Rami ^b   Lancet, Jeffrey ^b   Advani, Anjali S ^a   Afable, Manuel ^a   Englehaupt, Ricki ^a   Juersivich, Joyce ^a   Cuthbertson, David ^c   Paleveda, Jennifer ^b   Tabarroki, Ali ^a   Visconte, Valeria ^a   Makishima, Hideki ^a   Jerez, Andres ^a   Paquette, Ronald ^d   List, Alan F ^b   Maciejewski, Jaroslaw P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; LENALIDOMIDE;

ADULT; AGED; ARTICLE; BLEEDING; CHILL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIZZINESS; DNMT3A GENE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EDEMA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE; GENE MUTATION; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IDH1 GENE; IDH2 GENE; INFECTION; INJECTION SITE REACTION; INSOMNIA; KARYOTYPING; KIDNEY FAILURE; LUNG DISEASE; MALE; METASTASIS; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RIGOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; TET2 GENE; TREATMENT RESPONSE; VOMITING;

EID: 84869853588     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-434639     Document Type: Article

References (38)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
2. Vardiman J, Thiele J, Arber D, et al. The 2008 Revisions of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
3. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542-1551.
4. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
5. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465. (Pubitemid 44511560)
6. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440. (Pubitemid 34525728)
7. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
8. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009;106(31):12974-12979.
9. Wei S, Chen X, McGraw K, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion [published online ahead of print April 23, 2012]. Oncogene. doi: 10.1038/onc.2012.139.
10. Buesche G, Dieck S, Giagounidis A, et al. Antiangiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease [abstract]. Blood (ASH Annual Meeting Abstracts). 2005;106:113:Abstract 372.
11. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.
12. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87(10):1166-1172. (Pubitemid 35418112)
13. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86-93.
14. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010;28(33):4919-4925.
15. Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117(6):1828-1833.
16. Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011;118(3):523-528.
17. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315-1325.
18. Negrotto S, Hu Z, Link KA, et al. Differentiation-chronology specific function of DNMT1 and selective anti-leukemia stem-cell therapy [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract 201.
19. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-3776.
20. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010;28(13):2253-2258.
21. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425. (Pubitemid 44061337)
22. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
23. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
24. Maciejewski JP, Tiu RV, O'Keefe C. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol. 2009;146(5):479-488.
25. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111(3):1534-1542. (Pubitemid 351213443)
26. Database of geomic variants. http//projects.tcag.ca/variation/. Accessed February 4, 2009.
27. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
28. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27(11):1850-1856.
29. Sekeres MA, Maciejewski JP, Donley DW, et al. A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of myelodysplastic syndromes (MDS) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 3797.
30. List A, Kurtin S, Roe D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557. (Pubitemid 40204668)
31. Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26(36):5943-5949.
32. Adès L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2- or high risk myelodysplastic syndromes (MDS) with 5q deletion: results of a phase II study. Blood. 2009;113:3947-3952.
33. Sekeres MA, O'Keefe C, List AF, et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol. 2011;86(1):102-103.
34. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors of response and overall survival in 282 higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403-411.
35. Traina F, Jankowska A, Visconte V, et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118:Abstract 461.
36. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-1152.
37. Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012;26(5):893-901.
38. Sekeres M, List AF, Cuthbertson D, et al. Final results from a phase 1 combination study of lenalidomide and azacitidine in patients with higherrisk myelodysplastic syndromes (MDS) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 221.